22/10/2026 AstraZeneca commercializes ZEGFROVY® following US FDA approval in EGFR exon 20 insertion NSCLC AstraZeneca commercializes ZEGFROVY® following US FDA approval in EGFR exon 20 insertion NSCLC (Ref) AstraZeneca announced the US availability of ZEGFROVY® (sunvozertinib; EGFR-TKI), a targeted therapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations whose disease has progressed following

02/07/2025 Lynozyfic received accelerated approval from the US FDA for R/R Multiple Myeloma (Ref) Regeneron Pharmaceuticals announced that the US FDA granted accelerated approval for linvoseltamab-gcpt (Lynozyfic; BCMA x CD3 bispecific antibody) for patients with relapsed or refractory (R/R) multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody The accelerated a